Información del artículo
El microquimerismo fetal es la presencia de células fetalesen tejidos maternos y viceversa, es decir, la coexistencia de2 poblaciones celulares diferentes, originadas enindividuos genéticamente distintos, presentes en un soloindividuo. La causa más frecuente es el microquimerismoasociado al embarazo debido a un intercambiobidireccional de células feto-madre, lo cual sucededurante el embarazo y el parto.
Las células fetales se han demostrado en los tejidos depacientes con enfermedades reumatológicas, endocrinas oinfecciosas, así como en sujetos sanos.
La enfermedad en la que mejor se ha demostrado el papeldel microquimerismo es la esclerosis sistémica. Se sugiereque, durante el embarazo, las células fetales o maternasalógenas atraviesan la placenta de forma bidireccional ypersisten en la circulación y tejidos de ambos,posteriormente son activadas e inician una reaccióninjerto contra huésped, relacionada con el inicio de lasmanifestaciones clínicas. También se ha demostradoalgún papel del microquimerismo en otras enfermedadesdel tejido conectivo.
Palabras clave:
Microquimerismo
Complejo principalde histocompatibilidad
Esclerosis sistémica
Síndromede Sjögren
Hibridización in situ
Fetal microchimerism is the presence of fetal cells inmaternal tissues and vice versa, i.e., the coexistence of2 different cellular populations from genetically differentindividuals within a single person. The most frequentcause of microchimerism is pregnancy, in which there is abi-directional fetal-maternal interchange of cells duringpregnancy and delivery.
Fetal cells have been demonstrated in the tissues ofpatients with rheumatic, endocrine or infectious diseases,as well as in those of healthy individuals.
Microchimerism has been most extensively studied insystemic sclerosis. It seems that during pregnancyallogenic fetal or maternal cells cross the placenta bidirectionallyand persist in the systemic circulation andtissues of both mother and child. Subsequently, they areactivated, resulting in is a graft-against-host reactionassociated with the onset of clinical manifestations.Microchimerism has been also studied in otherconnective tissue diseases.
Key words:
Microchimerism
Major histocompatibilitycomplex
Systemic sclerosis
Sjögren’s syndrome
In situhybridization
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.L. Nelson.
Microchimerism and autoimmune disease.
N Engl J Med, 338 (1998), pp. 1224-1225
[2.]
A. Tanaka, K. Kindor, A. Ansari, E.M. Gershwin.
Fetal microchimerisms inthe mother: immunologic implications.
Liver Transplantation, 6 (2000), pp. 138-143
[3.]
K. Khosrotehrani, D.W. Bianchi.
Fetal cell microchimerism: helpful orharmful to the parous woman?.
Curr Opin Obstetrics Gynecology, 15 (2003), pp. 195-199
[4.]
K.M. Adams, J.L. Nelson.
Microchimerism: an investigative frontier in autoimmunityand transplantation.
JAMA, 291 (2004), pp. 1127-1131
[5.]
J.L. Nelson.
Longterm persistence of fetal and maternal cells: implicationsfor systemic sclerosis and other autoimmune diseases.
J Rheumatol, 27 (2000), pp. 2922-2926
[6.]
D. Bianchi.
Fetal cells in the mother: from genetic diagnosis to diseases associatedwith fetal cell microchimerism.
Eur J Obstetrics Gynecol, 92 (2000), pp. 103-108
[7.]
Y.M. Lo, S.F. Lo, N. Watson, L. Noakes, I.L. Sargent, B. Thilaganathan, et al.
Two-way cell traffic between mother and fetus: biologic and clinical implications.
Blood, 88 (1996), pp. 4390-4395
[9.]
M. Gannagé, Z. Amoura, O. Lantz, C. Piette J-, S. Caillat-Zucman.
Fetomaternalmicrochimerism in connective tissue diseases.
Eur J Immunol, 32 (2002), pp. 3405-3413
[10.]
C.M. Artlett, L.A. Cox, S.A. Jiménez.
Detection of Cellular microchimerismof male and female origin in systemic sclerosis patients by PCR analysis of HLA-CW alleles.
Arthritis Rheum, 43 (2000), pp. 1062-1067
[11.]
C.M. Artlett, L.A. Cox, S.A. Jiménez.
Detection of cellular microchimerismof male or female origin in systemic sclerosis patient by polymerase chainreaction analysis of HLA-Cw antigens.
Arthritis Rheum, 43 (2000), pp. 1062-1067
[12.]
F. Mullinax.
Chimerism in scleroderma.
Lancet, 351 (1998), pp. 1886
[13.]
L. Nelson.
Non-host cells in the pathogenesis of autoimmune disease: anew paradigm?.
Ann Rheum Dis, 58 (1999), pp. 518-520
[14.]
J.L. Nelson, D.E. Furst, S. Maloney, T. Gooley, P. Evans, A. Smith, et al.
Microchimerismand HLA-compatible relationships pf pregnancy in scleroderma.
Lancet, 351 (1998), pp. 559-562
[15.]
K. Khosrotehrani, K.L. Johnson, J. Lau, A. Dupuy, D. Hyun Cha, D.W. Bianchi.
The influence of fetal loss on the presence of fetal cell microchimerism.Arthriti?.
Rheum, 48 (2003), pp. 3237-3241
[16.]
P.C. Evans, N. Lambert, S. Maloney, D.E. Furst, J.M. Moore, J.L. Nelson.
Longtermfetal microchimerism in peripheral blood mononuclear cell subsets inhealthy women and women with scleroderma.
Blood, 93 (1999), pp. 2033-2037
[17.]
S.A. Jiménez, C.T. Derk.
Following the molecular pathways toward an understandingof the pathogenesis of systemic sclerosis.
Ann Intern Med, 140 (2004), pp. 37-50
[18.]
N. Lambert, S. Maloney, T. Hasizumi, D. Furst, C. Ober, L. Nelson.
Transgenerationalmicrochimerism, HLA compatibility and risk of systemicsclerosis.
Arthritis Rheum, 42 (1999), pp. S224
[19.]
C. Artlett, T. O’Hanlon, A. López, Y. Wook Song, F. Miller, L. Rider.
HLA-DQA1 is not an apparent risk factor for microchimerism in patientswith various autoimmune diseases and in healthy individuals.
ArthritisRheum, 48 (2003), pp. 2567-2572
[20.]
C. Scaletti, A. Vultaggio, S. Bonifacio, L. Emmi, F. Torricelli, E. Maggi, et al.
Th2-oriented profile of male offspring cells present in women with systemicsclerosis and reactive with maternal major histocompatibility complexantigens.
Arthritis Rheum, 46 (2002), pp. 445-450
[21.]
J.L. Nelson.
Pregnancy and microchimerism in autoimmune disease: protectoror insurgent?.
Arthritis Rheum, 46 (2002), pp. 291-297
[22.]
N. Lambert, T. Erickson, Z. Yan, J. Pang, K. Guthrie, D. Furst, et al.
Quantificationof maternal microchimerism by HLA-specific real-time polymerasechain reaction.
Arthritis Rheum, 50 (2004), pp. 906-914
[23.]
J.L. Nelson, N. Lambert, T. Medsger, B. Tsao, B. Hahn, M. McDonell, et al.
Persistent fetal and maternal microchimerism: a new etiology for autoimmunedisease?.
Arthritis Rheum, 42 (1999), pp. S277
[24.]
C. Artlett, B. Smith, S. Jiménez.
Identification of fetal DNA and cells inskin lesions from women with systemic sclerosis.
N Engl J Med, 338 (1998), pp. 1186-1191
[25.]
L. Kim, J. Korn.
Update in systemic sclerosis.
Arthritis Rheum (ArthritisCare and Research), 49 (2003), pp. 605-613
[26.]
F. Tan.
Systemic sclerosis: the susceptible host (genetics and environment).
Rheum Dis Clin North Am, 29 (2003), pp. 211-237
[27.]
N. Lambert, D. Lo, T. Erickson, T. Tylee, K. Guthrie, D. Furst, et al.
Malemicrochimerism in healthy women and women with scleroderma: cells orcirculating DNA? A quantitative answer.
Blood, 100 (2002), pp. 2845-2851
[28.]
Y. Miyashita, M. Ono, M. Ono, H. Ueki, K. Kurasawa.
Y chromosome microchimerismin rheumatic autoimmune disease.
Ann Rheum Dis, 59 (2000), pp. 655-656
[29.]
K. Johnson, L. Nelson, D. Furst, P. McSweenuy, D. Roberts, D. Zhen, et al.
Fetal cell microchimerism in tissue from multiple sites in women with systemicsclerosis.
Arthritis Rheum, 44 (2001), pp. 1848-1854
[30.]
D. Launay, M. Hebbar, P. Hatron, U. Michon-Pasturel, V. Queyrel, E. Hachulla, et al.
Relatioship between parity and clinical and biological featuresin patients with systemic sclerosis.
J Rheumatol, 28 (2001), pp. 509-513
[31.]
C. Artlett, M. Rasheed, K. Russo-Stieglitz, H. Sawaya, S. Jiménez.
Influenceof prior pregnancies on disease course and cause of death in systemic sclerosis.An?.
Rheum Dis, 61 (2002), pp. 346-350
[32.]
F. Pisa, M. Bovenzi, L. Romeo, A. Tonello, D. Biasi, L. Bambara, et al.
Reproductivefactors and the risk of scleroderma.
Arthritis Rheum, 40 (2002), pp. 451-456
[33.]
N. Ichikawa, S. Kotake, M. Hakoda, N. Kamatani.
Microchimerism in Japanesepatients with systemic sclerosis.
Arthritis Rheum, 44 (2001), pp. 1226-1228
[34.]
P. Roberts-Thompson, J. Walker, P. Hakendorf, M. Smith, M. Ahern.
Microchimerismin systemic sclerosis.
Arthritis Rheum, 46 (2002), pp. 2538-2548
[35.]
K. Welsh.
Scleroderma: chimerism, the blind man, and the scientist.
Lancet, 351 (1998), pp. 540-541
[36.]
S. Burastero, S. Galbiati, A. Vassallo, G. Sabbadini, M. Bellone, L. Marchionni, et al.
Cellular microchimerism as a lifelong physiologic status in parouswomen.
Arthritis Rheum, 48 (2003), pp. 1109-1116
[37.]
A. Callaghan, T. Mijares-Boeckh-Behrens, T. Balada Prades, R. Solans-Laque, C. Simeón-Aznar, V. Fonollosa-Pla, et al.
Lack of evidence of foetalmicrochimerism in female Spanish patients with systemic sclerosis.
Lupus, 12 (2003), pp. 15-20
[38.]
H. Murata, H. Nakauchi, T. Sumida.
Microchimerism in Japanese womenpatients with systemic sclerosis.
Lancet, 354 (1999), pp. 220
[39.]
F. Carlucci, R. Priori, G. Valesini.
Microchimerism in Sjögren syndrome.
Rheumatology, 42 (2003), pp. 486-487
[40.]
L. Martin, H. Watier, L. Vaillant, S. Aractingi.
Sjögren’s syndrome and vitiligoin a woman with posttransfusion microchimerism.
Am J Med, 111 (2001), pp. 419-421
[41.]
Y. Endo, I. Negishi, O. Ishikawa.
Possible contribution of microchimerismto the pathogenesis of Sjögren’s syndrome.
Rheumatology, 41 (2002), pp. 490-495
[42.]
M. Kuroki, A. Okayama, S. Nakamura, T. Sasaki, K. Murai, R. Shiba, et al.
Detection of maternal-fetal microchimerism in the inflammatory lesionsof patients with Sjögren syndrome.
Ann Rheum Dis, 61 (2002), pp. 1041-1046
[43.]
S. Aractingi, J. Sibilia, V. Meignin, D. Maunay, E. Hachulla, C. Le Danff, et al.
Presence of microchimerism in labila salivary glands in systemic sclerosisbut not in Sjögren’s syndrome.
Arthritis Rheum, 46 (2002), pp. 1039-1043
[44.]
F. Carlucci, R. Priori, C. Alessandri, G. Vlesini, A. Stoppacciaro.
Y chromosomemicrochimerism in Sjögren syndrome.
Ann Rheum Dis, 60 (2001), pp. 1078-1079
[45.]
R. Giacomelli, M. Matucci-Cerinic, S. Bombardieri.
Microchimerism inSjögren’s syndrome.
Ann Rheum Dis, 61 (2002), pp. 1039-1040
[46.]
I. Toda, M. Kuwana, K. Tsubota, Y. Kawakami.
Lack of evidence for an increasedmicrochimerism in the circulation of patients with Sjögren’s syndrome.An?.
Rheum Dis, 60 (2001), pp. 248-253
[47.]
K. Johnson, T. McAkindon, E. Mulcahy, D. Bianchi.
Microchimerism in afemale patient with systemic lupus erythematosus.
Arthritis Rheum, 44 (2001), pp. 2107-2111
[48.]
M. Mosca, M. Curcio, S. Lapi, G. Velenti, G. D’Angelo, G. Rizzo, et al.
Correlationsof Y chromosome microchimerism with disease activity in patientswith SLE: analysis of preliminary data.
Ann Rheum Dis, 62 (2003), pp. 651-654
[49.]
A. Filho, E. Pavarino-Bertelli, I. Alvarenga, R. Fernandes, E. Toledo, M. Tajara, et al.
Systemic lupus erythematosus and microchimerism in autoimmunity.
Transplantation Proceeding, 34 (2002), pp. 2951-2952
[50.]
A.M. Reed, L.P. Shock, Y.J. Picornell.
Microchimerism in children with juveniledermatomyositis.
Arthritis Rheum, 41 (1998), pp. S264
[51.]
A.M. Reed, Y. Picornell, A. Hardwood, D. Kredich.
Chimerism in childrenwith juvenile dermatomyositis.
Lancet, 356 (2000), pp. 2156-2157
[52.]
C. Artlett, R. Ramos, S. Jiménez, K. Patterson, F. Miller, L. Rider.
Chimericcells of maternal origin in juvenile idiopathic inflammatory myopathies.
Lancet, 357 (2001), pp. 887
[53.]
C. Artlett, F. Miller, L. Rider.
Persistent maternally derived peripheral microchimerismis associated with the juvenile idiopathic inflammatory myopathies.
Rheumatology, 40 (2001), pp. 1279-1284
[54.]
P. Christner, C. Artlett, R. Conway, S. Jiménez.
Increased circulating microchimericcells in mice following injections of vinyl chloride.
ArthritisRheum, 42 (1999), pp. S224
[55.]
P. Christner, C. Artlett, R. Conway, S. Jiménez.
Increased circulating microchimericcells in mice following injections of vinyl chloride.
ArthritisRheum, 43 (2000), pp. 2598-2605
Copyright © 2006. Elsevier España S.L. Barcelona
